Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 2/2012

01-04-2012 | Solicited Commentary

De-escalation strategies could be applied to a wide variety of infectious settings

Author: N. Shime

Published in: Infection | Issue 2/2012

Login to get access

Excerpt

To the Editor …
Literature
1.
Rolston KVI, Mahajan SN, Chemaly RF. Antimicrobial de-escalation in cancer patients. Infection 2011.
2.
Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011;39:319–25.PubMedCrossRef
3.
Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases of America and the Society for Healthcare Epidemiology of American guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRef
4.
Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest. 2001;119:426S–30S.PubMedCrossRef
5.
Safdar M, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136:834–44.PubMed
Metadata
Title
De-escalation strategies could be applied to a wide variety of infectious settings
Author
N. Shime
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Infection / Issue 2/2012
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0222-5

Other articles of this Issue 2/2012

Infection 2/2012 Go to the issue

Brief Report

No evidence of XMRV infection in immunocompromised patients and HIV-positive individuals from Germany

Clinical and Epidemiological Study

Lysis syndrome during therapy of visceral leishmaniasis

Clinical and Epidemiological Study

Under-notification of cryptosporidiosis by routine clinical and laboratory practices among non-hospitalised children with acute diarrhoea in Southern Spain

Case Report

Yersinia pseudotuberculosis bloodstream infection and septic arthritis: case report and review of the literature

Commentary

Implementing strategic bundles for infection prevention and management

Erratum

Erratum to: Miller–Fisher syndrome following vaccination against influenza virus A/H1N1 in an AIDS patient
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits